

1CellERA

Evidence | Research | Action

NOTE FROM THE CEO

A defining month for precision oncology

Dear Clinicians and Partners,

At **ASCO 2026**, the oncology community witnessed a landmark advance in metastatic pancreatic cancer with daraxonrasib, offering new hope in a disease where therapeutic progress has been limited for decades. It was a powerful reminder of how rapidly cancer care is evolving — and how essential precise molecular characterization has become in identifying the patients most likely to benefit from these new therapies.

At the same meeting, 1Cell — in collaboration with the Medical College of Wisconsin — presented research demonstrating that single-cell CTC profiling can reveal clinically relevant genomic alterations that remain undetected by conventional ctDNA analysis. As targeted therapies become more sophisticated, our diagnostic approaches must evolve to capture the full complexity of tumour biology.

That philosophy is also shaping the next chapter of **OncoIndx**[®]. We are now expanding beyond genomics to a truly multimodal approach — integrating *DNA, RNA and protein biomarkers* on a whole exome sequencing backbone to provide a more complete molecular portrait of each patient's cancer.

June also brought together our scientific, clinical, and commercial teams from across India for **IGNITE 2026**, our annual learning and development programme — ensuring that every interaction with 1Cell reflects the highest standards of scientific excellence and customer support.

Thank you for your continued trust and partnership. We look forward to continuing our shared mission of advancing precision oncology.



With gratitude,

Mohan Uttarwar

CEO, 1Cell.Ai

HIGHLIGHTS FROM 1CELL.AI

COMING SOON

The next generation of OncoIndx[®] — Comprehensive Multimodal Profiling



Comprehensive Multimodal Profiling
One test. Three dimensions.
The complete picture.

Precision oncology requires more than genomic alterations alone. As treatment options expand to include antibody-drug conjugates (ADCs), immunotherapies, and next-generation targeted therapies, clinicians need a fuller understanding of tumour biology. OncoIndx[®] is evolving into a multimodal platform that integrates **DNA, RNA and protein biomarkers** — a complete molecular portrait from a single blood sample.

LAYER	WHAT IT ADDS
Genomics on Whole Exome backbone	Expands beyond targeted panels to interrogate the entire protein-coding genome, enabling detection of rare, novel, and complex genomic alterations.
Whole Transcriptome Sequencing	Reveals which genes and biological pathways are actively expressed, complementing DNA findings and uncovering insights that genomic sequencing alone cannot provide.
Protein Biomarkers Profiling	Directly measures protein expression to identify actionable biomarkers for ADCs, immunotherapy selection, and emergence of treatment resistance.

Why it matters

Each layer tells a different part of the tumour's story. By integrating genomic, transcriptomic, and protein-level insights into a single report, OncoIndx[®] Multimodal helps clinicians identify actionable targets, understand resistance mechanisms, stratify patients for emerging therapies and trials, and make more informed treatment decisions.

IGNITE 2026

Investing in scientific excellence

At 1Cell, delivering the best solutions to clinicians begins with investing in our people. During **IGNITE 2026**, our annual commercial and scientific meeting, teams from across the country came together for an intensive week of learning, collaboration, and product deep dives.

The program focused on the latest developments across our oncology portfolio, evolving clinical evidence, real-world case discussions, and best practices for supporting oncologists in implementing precision medicine. Through interactive workshops and expert-led sessions, our teams aligned on a common goal — helping clinicians make faster, more informed treatment decisions with confidence.

"IGNITE was more than a sales meeting — it reaffirmed our commitment to equipping every member of the 1Cell team with the scientific knowledge and clinical understanding needed to be a trusted partner in precision oncology."

RESEARCH IN FOCUS

POSTER #4216 · MEDICAL COLLEGE OF WISCONSIN & 1CELL.AI · ASCO 2026

Why KRAS is only half the story in pancreatic cancer

While the world celebrated daraxonrasib's landmark KRAS results at ASCO 2026, our team — in collaboration with **Dr. Mandana Kamgar** and **Dr. Razelle Kurzrock** at the Medical College of Wisconsin Cancer Center — presented data that adds a crucial layer of nuance to that story. In 16 advanced metastatic PDAC patients profiled longitudinally using our OncoIncytes™ platform and OncoIndx™ 1080-gene panel:

65%

of all genomic alterations were detected **exclusively in single-cell CTC-DNA** — completely absent from matched ctDNA.

5

timepoints of longitudinal single-cell profiling captured **dynamic clonal evolution** and treatment-resistant subclones in real time.

— KRAS mutations found in ctDNA were absent in matched CTC-DNA in multiple patients, revealing **KRAS-independent circulating subclones** that would not respond to KRAS-targeted therapies.

— These subclones carry distinct oncogenic drivers — including **MAPK/RTK, PI3K-AKT-mTOR, and TGFβ/SMAD** pathways — that may be missed entirely by ctDNA profiling.

As KRAS-targeted therapies move toward approval, the diagnostic question becomes more important, not less. Identifying these patients before treatment begins — and monitoring clonal evolution in real time — is precisely what our single-cell CTC platform is built to do.

[Read the full poster publication →](#)

TOP NEWS IN ONCOLOGY · JUNE 2026

01 KRAS unlocked: Daraxonrasib nearly doubles survival in metastatic pancreatic cancer

In the most anticipated presentation of ASCO 2026, Revolution Medicines' daraxonrasib delivered a landmark result in previously treated metastatic PDAC: median OS of **13.2 months vs 6.6 months** with chemotherapy — a 60% reduction in risk of death (HR 0.40, p<0.0001).

[Read on AJMC →](#)

02 OPTIMA trial: Two-thirds of high-risk breast cancer patients can safely skip chemotherapy

The OPTIMA trial at ASCO 2026 showed that using the Prosigna genomic test to guide adjuvant therapy allowed two-thirds of patients who would otherwise have received chemotherapy to safely de-escalate — without compromising outcomes.

[Read on TechTimes →](#)

03 AI moves from hype to standard of care

City of Hope's 2026 predictions are coming true: digital pathology and multi-omics AI are becoming standard in oncology workflows, with AI agents independently uncovering meaningful clinical insights from large genomic datasets.

[Read on City of Hope →](#)

04 Precision medicine is no longer about matching a drug with a target

At the AACR 2026 plenary, MD Anderson's Katy Rezvani declared that precision medicine is now about selecting the right therapeutic platform for the biology in front of us. Radiotherapeutics, ADCs, T cell engagers, and TILs took centre stage as the new toolkit of precision oncology.

[Read on The Scientist →](#)



Follow Us



We can help you implement precision oncology in your everyday practice

Write to us at info@1cell.ai